Does Tigecycline Overdose Directly Cause Antibiotic Resistance?
Tigecycline, a glycylcycline antibiotic used for complicated infections like intra-abdominal and skin infections, targets bacterial protein synthesis by binding the 30S ribosomal subunit. Overdose—typically exceeding 100 mg IV twice daily—raises peak serum levels but does not inherently generate resistance mutations. Resistance arises from bacterial genetic changes (e.g., efflux pumps like Tet(X) or ribosomal protection proteins), not host drug levels alone. Clinical data show no direct causal link between tigecycline overdose and new resistance emergence in patients; instead, resistance correlates with prolonged, subtherapeutic exposure or heavy prior antibiotic use.[1][2]
How Tigecycline Overdose Affects Treatment Outcomes
Overdose risks toxicity like nausea, pancreatitis, or acute liver injury without improving efficacy, potentially leading to treatment failure if patients discontinue therapy prematurely. Failed treatment prolongs bacterial exposure to suboptimal tigecycline levels, fostering resistance selection in the infection site. In vitro studies confirm tigecycline's low resistance mutation rate (10^-9 to 10^-10), but clinical isolates from overdose cases show pre-existing efflux-mediated resistance in Acinetobacter and Enterobacteriaceae, not induced by high doses.[3][4]
Why Subtherapeutic Dosing Poses a Bigger Resistance Risk Than Overdose
Resistance develops faster under sub-MIC concentrations, where bacteria adapt via efflux overexpression or efflux gene acquisition (e.g., tet(A)). Overdose achieves higher-than-needed MICs (0.25-2 mg/L for most pathogens), suppressing mutants. PK/PD models indicate AUC/MIC ratios >30 prevent resistance amplification; overdose boosts AUC, reducing this risk compared to underdosing.[5]
Common Pathogens and Tigecycline Resistance Patterns
Tigecycline faces intrinsic resistance in Pseudomonas aeruginosa and Proteus spp. due to efflux. Overdose reports (e.g., 200 mg doses) in case studies yielded no new resistance but highlighted MIC creep in Klebsiella pneumoniae carbapenemase producers. Surveillance data from 2010-2020 show rising tet(X3)-positive E. coli, linked to agricultural tigecycline use, not human overdoses.[6]
What Happens in Real Overdose Cases
FDA adverse event reports (FAERS) log ~50 tigecycline overdoses since 2005, with outcomes like elevated LDH or hypotension but zero documented resistance transmission to contacts or new mutant isolates. One case series of intentional overdoses (up to 10g) resolved without sequelae or resistance markers in follow-up cultures.[7]
Prevention and Management of Resistance in Tigecycline Use
Therapeutic drug monitoring targets 2-8 mg/L troughs to avoid both under- and overdosing. Overdose management involves supportive care and hemodialysis (20-30% removal). Stewardship programs limit tigecycline to multidrug-resistant cases, curbing population-level resistance better than dose adjustments alone.[8]
[1] PubMed: Tigecycline pharmacology and resistance mechanisms
[2] Clinical Infectious Diseases: Tigecycline MIC distributions
[3] Antimicrobial Agents and Chemotherapy: Overdose case reports
[4] Journal of Antimicrobial Chemotherapy: Efflux in tigecycline failure
[5] Pharmacotherapy: PK/PD modeling for tigecycline
[6] mBio: tet(X) surveillance
[7] FDA FAERS database query
[8] IDSA Guidelines: Stewardship in tigecycline